Swiss edition Data as at end-October 2024

For qualified investors only

UBS China A Opportunity Equity Fund USD (CAD) I-B-acc

Fund Fact Sheet

Equity > Asia > Emerging Markets

Fund description


- The actively managed fund invests principally in Chinese firms and the majority of net assets are invested in China A Shares, which are stocks in Chinese companies that are registered in China's local markets and can only be traded by the local Chinese and selected foreign institutional investors who are allotted Qualified Foreign Institutional Investors ("QFII") quota.
- The Fund is managed by a team of experienced equity specialists who are well-acquainted with the Chinese financial markets.
- The portfolio manager is not tied to the benchmark in terms of investment selection or

Name of fund	LIDC /L	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Name of Tund	OB2 (Lux	() Investment SICAV - China A
		Opportunity (USD)
Share class		Lux) Investment SICAV - China A
		Opportunity (USD) (CAD) I-B-acc
ISIN		LU2713907694
Securities no.		130 583 469
Bloomberg		UBCOCIB LX
Reuters		n.a.
Currency of fund / sh	are class	USD/CAD
Launch date		27.11.2023
Issue/redemption		daily
Swing pricing		yes
Accounting year end		31 January
Benchmark MS	CI China A	Onshore (net div. reinv.) in CAD
Distribution		Reinvestment
Management fee p.a		0.00%
Minimum investmen		_
Ongoing costs p.a. ¹		0.18%
Name of the Manage	ement	UBS Asset Management
Company		(Europe) S.A., Luxembourg
Fund domicile		Luxembourg
SFDR Alignment		Art.8
1 As at 18.10.2024, with	out transacti	on costs

Fund Statistics

Net asset value (CAD, 31.10.2024)	107.96
Last 12 months (CAD) – high	115.31
– low	88.38
Total fund assets (CAD m)	1 729.14
Share class assets (CAD m)	5.18

Performance (basis CAD, net of fees)1



Fund performance net of fees (left-hand scale)

..... Benchmark (left-hand scale)

Past performance is not a reliable indicator of future results.

in %	2021	2022	2023	2024	Oct.	LTD3	Ø p.a.	Ø p.a.
				YTD ²	2024		3 years	5 years
Fund (CAD)	n.a.	n.a.	n.a.	15.87	-3.71	7.96	n.a.	n.a.
Benchmark ⁴	n.a.	n.a.	n.a.	20.79	0.32	15.13	n.a.	n.a.

The performance shown does not take account of any commissions, entry or exit charges.

- These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset
- Management. YTD: year-to-date (since beginning of the year) LTD: launch-to-date Reference Index in currency of share class (without costs)

Name changed on 24.11.2016: from UBS (Lux) Institutional SICAV II - China A Opportunity (USD) to UBS (Lux) Investment SICAV - China A Opportunity (USD)

in %	05.2024	06.2024	07.2024	08.2024	09.2024	10.2024
Fund (CAD)	-1.94	-3.79	-0.03	-1.87	19.28	-3.71
Benchmark	-1.74	-3.28	1.60	-4.31	23.37	0.32

Key Figures

	2 years	3 years	5 years
Beta	n.a.	n.a.	n.a.
Correlation	n.a.	n.a.	n.a.
Volatility ¹			
– Fund	n.a.	n.a.	n.a.
— Benchmark	n.a.	n.a.	n.a.
Tracking error (ex post)	n.a.	n.a.	n.a.
Information ratio	n.a.	n.a.	n.a.
Sharpe ratio	n.a.	n.a.	n.a.
Risk free rate	n.a.	n.a.	n.a.
R2	n.a.	n.a.	n.a.
4 A E I			

¹ Annualised standard deviation

For more information

UBS Fund Infoline: 0800 899 899 Internet: www.ubs.com/funds Contact your client advisor

Portfolio management representatives

Bin Shi Morris Wu Denise Cheung

UBS China A Opportunity Equity Fund USD (CAD) I-B-acc

Sector exposure (%)

Sectors	Portfolio
Health Care	24.27
Financial Services	20.14
Consumer Staples	15.32
Information Technology	14.50
Cash	12.02
Utility	11.03
Industrials	1.70
Communication Services	0.63
Consumer Discretionary	0.39
Real estate	0.00
Materials	0.00
Energy	0.00

10 largest equity positions (%)¹

	Fund
China Merchants Bank Co Ltd	9.5
Kweichow Moutai Co Ltd	9.2
Yunnan Baiyao Group Co Ltd	8.6
Fuyao Glass Industry Group Co Ltd	6.3
Midea Group Co Ltd	5.3
Inner Mongolia Yili Industrial Group Co Ltd	4.9
Tencent Holdings Ltd	4.3
Dong-E-E-Jiao Co Ltd	3.8
NetEase Inc	3.7
Jiangsu Hengrui Pharmaceuticals Co Ltd	3.4

¹ This is not a recommendation to buy or sell any security

Benefits

Easy access to investment opportunities provided by a rapidly growing Chinese economy. Investors gain access to local Chinese shares, e.g. China A shares.

An experienced portfolio management team, that can leverage local investment expertise in the Chinese market via our joint venture UBS SDIC in China

Risks

UBS Opportunity Equity Funds invest in equities and may therefore be subject to high fluctuations in value. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of it's reference index. All investments are subject to market fluctuations. This Fund has specific risks related to Chinese investments, which can significantly increase given the specific market and market regulation. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our ruture business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. **Switzerland:** Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.